BioNTech’s (BNTX) Sell (D-) Rating Reaffirmed at Weiss Ratings

Weiss Ratings reaffirmed their sell (d-) rating on shares of BioNTech (NASDAQ:BNTX) in a report released on Tuesday,Weiss Ratings reports.

Other equities research analysts have also recently issued reports about the company. Bank of America increased their price objective on BioNTech from $126.00 to $134.00 and gave the company a “buy” rating in a research report on Tuesday, August 5th. JPMorgan Chase & Co. increased their price objective on BioNTech from $116.00 to $121.00 and gave the stock a “neutral” rating in a research note on Monday, September 22nd. Wells Fargo & Company set a $150.00 price objective on BioNTech and gave the stock an “overweight” rating in a research note on Tuesday, August 5th. HC Wainwright restated a “buy” rating and issued a $136.00 target price on shares of BioNTech in a research note on Monday, September 8th. Finally, Morgan Stanley decreased their price target on BioNTech from $133.00 to $131.00 and set an “overweight” rating on the stock in a report on Friday. Ten equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, BioNTech presently has an average rating of “Moderate Buy” and a consensus price target of $134.32.

BioNTech Trading Up 0.3%

NASDAQ:BNTX opened at $102.61 on Tuesday. The company has a market capitalization of $24.67 billion, a P/E ratio of -64.13 and a beta of 1.45. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.48 and a current ratio of 8.61. The stock’s 50 day moving average price is $104.15 and its 200 day moving average price is $103.68. BioNTech has a 52 week low of $81.20 and a 52 week high of $129.27.

BioNTech (NASDAQ:BNTX) last announced its earnings results on Monday, August 4th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.41) by ($0.19). The company had revenue of $306.46 million for the quarter, compared to the consensus estimate of $161.26 million. BioNTech had a negative return on equity of 1.84% and a negative net margin of 12.20%.The firm’s revenue for the quarter was up 102.6% compared to the same quarter last year. During the same period in the previous year, the company earned ($3.36) EPS. BioNTech has set its FY 2025 guidance at EPS. On average, research analysts forecast that BioNTech will post -3.88 EPS for the current fiscal year.

Institutional Investors Weigh In On BioNTech

Hedge funds and other institutional investors have recently bought and sold shares of the company. Dodge & Cox acquired a new position in shares of BioNTech during the 2nd quarter worth approximately $93,421,000. Bank of New York Mellon Corp increased its position in shares of BioNTech by 18,892.9% during the 1st quarter. Bank of New York Mellon Corp now owns 698,368 shares of the company’s stock worth $63,593,000 after purchasing an additional 694,691 shares during the last quarter. BNP Paribas Financial Markets increased its holdings in shares of BioNTech by 94.6% during the 1st quarter. BNP Paribas Financial Markets now owns 1,195,470 shares of the company’s stock worth $108,859,000 after acquiring an additional 581,173 shares during the last quarter. Invesco Ltd. increased its holdings in shares of BioNTech by 643.7% during the 1st quarter. Invesco Ltd. now owns 645,142 shares of the company’s stock worth $58,747,000 after acquiring an additional 558,389 shares during the last quarter. Finally, Millennium Management LLC increased its holdings in shares of BioNTech by 252.5% during the 1st quarter. Millennium Management LLC now owns 544,970 shares of the company’s stock worth $49,625,000 after acquiring an additional 390,360 shares during the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.